Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

Loretta Fiorillo, Emily Becker, Raul de Lucas, Anna Belloni-Fortina, Susana Armesto, Peter Maes, Rajneet Oberoi, Maria Paris, Wendy Zhang, Zuoshun Zhang, Lisa Arkin

Page s109

Poster PDF

Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study

Joseph Merola, Lawrence Parish, Lyn Guenther, Charles Lynde, Jean-Philippe Lacour, Petra Staubach, Sue Cheng, Shauna Jardon, Maria Paris, Mindy Chen, Kim Papp

Page s110

Poster PDF

Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial

Mark Lebwohl, Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, David Adam, H. Chih-ho Hong, Leon Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, David Krupa, David Berk

Page s111

Poster PDF

Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years

April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov

Page s112

Poster PDF

Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy

Sang Hee Park, Yichen Zhong, Adam Sima, Vardhaman Patel, Joe Zhuo, Carla Roberts-Toler, Brandon Becker, Sara Hovland, Bruce Strober

Page s113

Poster PDF

Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study

Victoria P. Werth, Marilyn Pike, Joan T. Merrill, Eric Morand, Ronald van Vollenhoven, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

Page s114

Poster PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials

Mark Lebwohl, Bruce Strober, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Nehal N. Mehta

Page s115

Poster PDF

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

Mark Lebwohl, Alexander Egeberg, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Bruce Strober

Page s116

Poster PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher EM Griffiths

Page s117

Poster PDF

Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt

Page s118

Poster PDF

Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program

Neil J. Korman, Thierry Passeron, Kenneth B. Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B. Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Diamant Thaçi

Page s119

Poster PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

April W. Armstrong, Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, Bruce Strober

Page s120

Poster PDF

Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

David Burden, Yukari Okubo, Min Zheng, Diamant Thaci, Peter van de Kerkhof, Na Hu, Christian Thoma, Siew Eng Choon

Page s121

Poster PDF

Global consensus on the clinical course, treatment and management of generalized pustular psoriasis (GPP)

Lluis Puig, Siew Eng Choon, Alice Gottlieb, Slaheddine Marrakchi, Jörg Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda Gooderham

Page s122

Poster PDF

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Linda Stein Gold, Christopher E. M. Griffiths, Anna Tallman, Philip M. Brown, Mark G. Lebwohl

Page s123

Poster PDF

Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis

April W. Armstrong, Robert Bissonnette, Phililp M. Brown, Anna Tallman, Kim A. Papp

Page s124

Poster PDF

Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial

Bruce Strober, Joshua A. Zeichner, Seemal R. Desai, Michael Cameron, Jennifer Cather, Matthew J. Bruno, David S. Rubenstein, Anna Tallman, Philip M. Brown

Page s125

Poster PDF

Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis

Leon Kircik, Mathew Zirwas, Shawn G. Kwatra, Michael Lewitt, Holly Glover, Tomas Chao, Philip M. Brown, David S. Rubenstein, Anna Tallman

Page s126

Poster PDF

Patient Perspectives on use of a water-based Calcipotriene and Betamethasone Dipropionate Cream for the treatment of Plaque Psoriasis

Michael Vecchiolla, Neal Bhatia

Page s127

Poster PDF

Phase 3 Trial Demonstrating High Efficacy, Favourable Safety, and Convenience of a Novel Calcipotriene and Betamethasone Dipropionate Cream

Linda Stein Gold, Andreas Pinter, April Armstrong, Lars Iversen, Morten Praestegaard, Matthias Augustin

Page s128

Poster PDF

Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials

Alexa B Kimball, Afsaneh Alavi, Gregor BE Jemec, Alice Gottlieb, Xiaoling Wei, Magdalena B Wozniak, Lorenz Uhlmann, Angela Llobet Martinez, Deborah Keefe, Ruvie Martin, Li Chen, Elisa Muscianisi

Page s129

Poster PDF

Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety

Lawrence Green, Jerry Bagel, George Han, Abby Jacobson, Martha Sikes

Page s130

Poster PDF

Use of Combination Halobetasol Propionate/Tazarotene Lotion in Difficult-to-Treat Psoriasis and TNF-α Mechanism of Action

Leon Kircik, Zoe Draelos, Linda Stein Gold, Abby Jacobson

Page s131

Poster PDF

Brodalumab: 4-Year US Pharmacovigilance Report

Mark Lebwohl, Andrea Murina, George Han, Abby Jacobson

Page s132

Poster PDF

Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis

April Armstrong, Mark Lebwohl, Linda Stein Gold, Abby Jacobson

Page s133

Poster PDF

Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis

Neal Bhatia, J Gabriel Vasquez, Brad Schenkel, Jayme Heim

Page s134

Poster PDF

Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis

Jayme Heim, J Gabriel Vasquez, Brad Schenkel, Neal Bhatia

Page s135

Poster PDF

Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Alan M Menter, Zoe Draelos, Jayme Heim, Ranga Gogineni, Christopher EM Griffiths

Page s136

Poster PDF

Alopecia

Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib

Brett King, Jerry Shapiro, Manabu Ohyama, Alexander Egeberg, Yves Dutronc, Yun-Fei Chen, Wen-Shuo Wu, Yuxin Ding, Najwa Somani, Rodney Sinclair

Page s184

Poster PDF

Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program

Maryanne Senna, Ohsang Kwon, Bianca Piraccini, Rodney Sinclair, Susan Ball, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Brett King

Page s185

Poster PDF

Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

Bianca Maria Piraccini, Manabu Ohyama, Brittany Craiglow, Anthony Bewley, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Evangeline Pierce, Frederick Durand, Arash Mostaghimi

Page s186

Poster PDF

Evaluation of Response to Ritlecitinib Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Ulrike Blume-Peytavi, Walter Gubelin Harcha, Qinping Yang, George Schmieder, Maria Hordinsky, Giuseppe Micali, Manabu Ohyama, Liza Takiya, Fan Zhang, Gregor Schaefer, Robert Wolk, Urs Kerkmann

Page s187

Poster PDF

Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Robert Wolk, Samuel Zwillich, Helen Tran , Fan Zhang, Liza Takiya

Page s188

Poster PDF

Skin Cancer

Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)

Leon Kircik, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s161

Poster PDF

Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)

Todd Schlesinger, Leon Kircik, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s162

Poster PDF

Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)

Georgina V. Long, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaëlle Quéreux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, John M. Kirkwood

Page s163

Poster PDF

Incorporating the 40-gene expression profile (40-GEP) test for poorly differentiated cutaneous squamous cell carcinoma (cSCC) tumors mitigates risk assessment uncertainty from histologic grading

Aaron Farberg, Jennifer Siegel, Sarah Kurley, Alison Fitzgerald, Anesh Prasai, Matthew Goldberg, Sherrif Ibrahim, Sarah Estrada

Page s164

Poster PDF

Integration of the 40-Gene Expression Profile (40-GEP) for Management and Treatment of High-risk Cutaneous Squamous Cell Carcinoma (cSCC): A Real-world Algorithm

Gaurav Singh, Stan Tolkachjov, Aaron Farberg

Page s165

Poster PDF

A clinical impact study of dermatologists’ use of the 23- or 35-gene expression profile tests to guide surgical excision and enhance management plan confidence

Aaron S Farberg, Kelli L Ahmed, Briana B Rackley, Jennifer J Siegel, Brooke H Russell, Jason H Rogers, Sarah J Kurley, Matthew S Goldberg

Page s166

Poster PDF

Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma

Brian Martin, Christine Bailey, Matthew Goldberg, Valentina Petkov, Robert Cook, Kyle Covington, Sarah Kurley

Page s167

Poster PDF

Clinical use of the 31-gene expression profile for informing sentinel lymph node biopsies: a prospective, multicenter study

J. Michael Guenther, Christine N. Bailey, Kelli Ahmed, Clare Johnson, Brian Martin, Sarah Kur, Maki Yamamoto

Page s168

Poster PDF

Genomic Profiling of Lentigo Maligna within an Interim Registry Analysis

Greg Stevens, James Rock, Burkhard Jansen, Terry Arnold, Jennifer Wood, Loren Clarke, Mark Hyde

Page s169

Poster PDF

Concordance of Preferentially Expressed Antigen in Melanoma by Non-Invasively Collected Polymerase Chain Reaction and Immunohistochemistry on Paraffin Embedded Tissue

Greg Stevens, Burkhard Jansen, Terry Arnold, James Rock, Jennifer Wood, Loren Clarke, Mark Hyde

Page s170

Poster PDF

Visual Assessment and Dermoscopy Enhanced by Non-invasive Genomic Testing

Gary Peck, Rachel Reifer, Mark Hyde, Sarah Matthews, Burkhard Jansen, Maral Skelsey

Page s171

Poster PDF

Intralesional Treatment of Basal Cell Carcinoma in a Genetically Inducible Mouse Model

Nancy Messier, PhD, Frédéric Couture, PhD, Vanessa Théberge, MSc, Mario Harvey, MSc, Kenneth Kobayashi, MD FRCPC FAAD

Page s172

Poster PDF

C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma

Danny Rischin, Daniel Brungs, Fiona Day, Hayden Christie, Vishal Patel, Gerard Adams, James Estes Jackson, Maite De Liz Vassen Schurmann, Dmitry Kirtbaya, Thuzar Shin, Christopher Hart, Elizabeth Stankevich, Siyu Li, Israel Lowy, Hyunsil Han, Priscila Gonçalves, Matthew Fury, Sandro Porceddu

Page s173

Poster PDF

CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting

Guilherme Rabinowits, Jade Homsi, Soo Park, Nikhil Khushalani, Timothy Panella, David Ellison, Rhonda Gentry, Suraj Venna, John Strasswimmer, Richard Zuniga, Sunandana Chandra, Emily Ruiz, Michael Migden, Sherrif Ibrahim, Nikita Mehta, Timothy Inocencio, Xuanyao He, Haixin Zhang, Kathryn Gillis, Jean-Francois Pouliot

Page s174

Poster PDF

Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

Brett Hughes, Jean-Jacques Grob, Samantha Bowyer, Fiona Day, Rahul Ladwa, Brian Stein, Eva Muñoz-Couselo, Nicole Basset-Seguin, Alexander Guminski, Laurent Mortier, Axel Hauschild, Michael Migden, Chrysalyne Schmults, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin

Page s175

Poster PDF

Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3

Michael Migden, Chrysalyne Schmults, Nikhil Khushalani, Alexander Guminski, Anne Lynn Chang, Karl Lewis, George Ansstas, Samantha Bowyer, Brett Hughes, Dirk Schadendorf, Badri Modi, Lara Dunn, Lukas Flatz, Axel Hauschild, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin

Page s176

Poster PDF

Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors

Karl D Lewis, Ketty Peris, Aleksandar Sekulic, Alexander J Stratigos, Lara Dunn, Zeynep Eroglu, Anne Lynn S Chang, Michael R Migden, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Emmanuel Okoye, Jean-François Baurain, Oliver Bechter, Axel Hauscild, Marcus O Butler, Leonel Hernandez-Aya, Lisa Licitra, Rogerio I Neves, Emily S Ruiz, Frank Seebach, Israel Lowy, Priscila Goncalves, Matthew G Fury

Page s177

Poster PDF

Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up

Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, Nicole Basset-Seguin, Anne Lynn S Chang, Stéphane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R Migden, Reinhard Dummer, Suk-Young Yoo, Ebony Coates, Emmanuel Okoye, Ioannis Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Israel Lowy, Matthew G Fury

Page s178

Poster PDF

Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis

Omid Hamid, Karl Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Nehal J Lakhani, John Kaczmar, Ragini Kudchadkar, Alexander Spira, Guilherme Rabinowits, Kevin Kim, Richard Carvajal, Stephen Williamson, Ella Ioffe, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Laura Brennan, Glenn Kroog, Tasha Sims, Israel Lowy, Giuseppe Gullo

Page s179

Poster PDF

Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Michael Migden, Alexander Guminski, Ralf Gutzmer, Carmen Loquai, Nicholas Squittieri, Peter Foley

Page s180

Poster PDF

Biochemistry laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Alexander Guminski, Peter Foley, Jean-Jacques Grob, Caroline Robert, Ralf Gutzmer, Nicholas Squittieri, Felix Kiecker

Page s181

Poster PDF

Optimizing the Pharmacokinetics of Sonidegib in Small Bowel Syndrome and Advanced Basal Cell Carcinoma: Our Solution

Hailey Grubbs, Marianne Cortes, John Strasswimmer

Page s182

Poster PDF

The efficacy and safety of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light for the treatment of facial cutaneous squamous cell carcinoma in situ

Mark S Nestor, Haowei Han, Faraz Yousefian, Ciaran Smythe

Page s183

Poster PDF

Acne & Rosacea

Acne symptoms and impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among pediatric patients with moderate to severe non-nodular Acne Vulgaris (AV) in community practices across the U.S: PROSES study

Adelaide Hebert, Evan Rieder, Emmy Graber, Hilary Baldwin, Julie C. Harper, Linda Stein Gold, Leon Kircik, Andrew F. Alexis, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Richard G. Fried

Page s155

Poster PDF

Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age

Emmy Graber, Hilary Baldwin, Julie C. Harper, Linda Stein Gold, Andrew F. Alexis, Richard G. Fried, Evan Rieder, James Del Rosso, Leon Kircik, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Adelaide Hebert

Page s156

Poster PDF

Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication

Hilary Baldwin, James Del Rosso, Leon Kircik, Linda Stein Gold, Adelaide Hebert, Evan A. Rieder, Andrew F. Alexis, Julie C. Harper, Richard G. Fried, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Emmy Graber

Page s157

Poster PDF

Comparison of Cutaneous Irritation With Repeated Application of Tazarotene 0.045% Lotion, Adapalene 0.3% Gel, and Trifarotene 0.005% Cream

Zoe D. Draelos, MD, Patricia Farris, MD, Hilary Baldwin, MD, Emil A Tanghetti, MD

Page s158

Poster PDF

Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug

Linda Stein Gold, MD, Leon H. Kircik, MD, Emil A Tanghetti, MD, Hilary Baldwin, MD, Zoe D. Draelos, MD, Michael Gold, MD, Edward Lain, MD, MBA, David M Pariser, MD, Neil Sadick, MD, Radhakrishnan Pillai, PhD, Varsha Bhatt, PhD

Page s159

Poster PDF

Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris

Lawrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, Martina Cartwright, Luigi Moro, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti

Page s160

Poster PDF

Miscellaneous

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial

Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu

Page s196

Poster PDF

Survey Results Identifying Clinician Strategies for Therapy Selection for Common Inflammatory Skin Diseases

Nicholas D. Brownstone, Aaron S. Farberg, Ann P. Quick, Jennifer J. Siegel, Matthew S. Goldberg, Peter A. Lio

Page s197

Poster PDF

Non-Invasive Genomic Profiling in Pediatric Patients

Allyson Perry, Danielle Ruppenthal, Kellie Hill

Page s198

Poster PDF

A Pilot Study, to Evaluate the Safety and Efficacy of Topically Applied Onabotulinum Toxin A Delivered through a Novel Iontophoresis Device in Subjects with Axillary Hyperhidrosis

Mark Nestor, Haowei Han, Anita Gade, Francesca Ceci, Alec Lawson, Austin Dunn, Faraz Yousefian, Ciaran Smythe

Page s199

Poster PDF

Quality of Information on Molluscum Contagiosum Consumer Websites

Elaine Siegfried , Samantha Ong, Jennifer Andres, Christine Crosby, Melissa Olivadoti

Page s200

Poster PDF

Disorders of Pigmentation

Efficacy of a Targeted Pigment-Correcting Spot Treatment Cream for Post-inflammatory Hyperpigmentation and Solar Lentigines in a 12-Week, Single-Center Clinical Study

Elizabeth T. Makino, BS, CCRA, MBA, Priscilla Huang, BA, Summer F. Acevedo, PhD, Cristiane de Oliveira, PhD, Rahul C. Mehta, PhD

Page s189

Poster PDF

Efficacy of Novel Multimodality Pigment-Correcting Serum for Moderate to Severe Facial Hyperpigmentation, Including Melasma, in a 12-Week, Split-Face, Double-blind, Randomized Controlled Trial

Elizabeth T. Makino, BS, CCRA, MBA, Priscilla Huang, BA, Summer F. Acevedo, PhD, Cheryl Vaughan, PhD, Rahul C. Mehta, PhD

Page s190

Poster PDF

Efficacy and Tolerability of Novel Topical Pigment-Correcting Serums With Biweekly Diamond Tip Microdermabrasion Treatments on Facial Hyperpigmentation (HP), Including Melasma and Post-inflammatory HP

Lisa Goberdhan, MSHS, Katie Schneider, BS, Elizabeth T. Makino, BS, CCRA, MBA, Rahul C. Mehta, PhD

Page s191

Poster PDF

Evaluation of a Novel Inorganic Tinted Sunscreen Enriched with Five Antioxidants for Protection Against UVA1 and VL Induced Hyperpigmentation and Erythema

Omid Yousefian, Lisa Aeschliman, Susan Mortillo, Eduardo Ruvolo

Page s192

Poster PDF

Dermatopharmacology

Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases

Olga Ostrovskaya, Magdalena Sips, Peter Ulrichts, Lance Trainor, Peter Verheesen, Ivaylo Stoykov

Page s193

Poster PDF

Tapinarof Inhibits the Formation, Cytokine Production, and Persistence of Resident Memory T Cells In Vitro

Nathan Mooney, Jessica E. Teague, Ahmed E. Gehad, Kimberly McHale, David S. Rubenstein, Rachael A. Clark

Page s194

Poster PDF

Efinaconazole in the Age of Antifungal Resistance

Ahmed Gamal, Mohammed Elshaer, Lisa Long, Thomas S. McCormick, Boni Elewski, Mahmoud A. Ghannoum

Page s195

Poster PDF

Atopic Dermatitis

Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application

James Del Rosso, Scott Guenthner, Chih-ho Hong, John E Jett, Philip M. Brown, David S. Rubenstein, Stephen Piscitelli

Page s137

Poster PDF

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Amy Paller, Adelaide A. Hebert, John E Jett, Philip M. Brown, David S. Rubenstein, Stephen Piscitelli

Page s138

Poster PDF

The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Amy Paller, Jonathan Silverberg, H. Chih ho Hong, Michael Cork, Luis Puig, Petra Arlert, Azra Kurbasic, Lise Soldbro, Eric Simpson

Page s139

Poster PDF

Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Michael Cork, Carsten Flohr, Anthony Bewley, Andrew Blauvelt, Chih-ho Hong, Shinichi Imafuku, Marie L.A. Schuttelaar, Eric Simpson, Weily Soong, Petra Amoudruz, Katja Wendicke Lophaven, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Amy Paller

Page s140

Poster PDF

Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials

Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew Alexis

Page s141

Poster PDF

3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis

Richard Warren, Kristian Reich, Eric Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Anna Carlsson, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt

Page s142

Poster PDF

Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest

Kristian Reich, Eric Simpson, Richard Langley, Richard Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, Andrew Blauvelt

Page s143

Poster PDF

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew Alexis

Page s144

Poster PDF

Real World Baseline Characteristics and Early Patient Reported Outcomes in Adult Patients with Moderate to Severe Atopic Dermatitis Treated with Tralokinumab

Peter Lio, Yestle Kim, Sanjeev Balu, Adriana Guana, Dawn Bates, deMauri Mackie, Halley Costantino, Amanda Lopez, Jennifer Soung

Page s145

Poster PDF

Understanding Flares in Pediatric and Adolescent Patients with Moderate or Severe Atopic Dermatitis: A Real-world Study in the United States and Europe

Lawrence Eichenfield, Vivian Shi, JiaDe Yu, Evangeline Pierce, Amber Reck Atwater, Jenny Austin, Phoebe Salmon, James Piercy, Peter Anderson, Amy Paller

Page s146

Poster PDF

Lebrikizumab Monotherapy Reduces Flares in Patients with Moderate-to-Severe Atopic Dermatitis

James Q. Del Rosso, Pearl Kwong, Iftikhar Hussain, Sebastien Barbarot, Jose Manuel Carrascosa, Maria Jose Rueda, Amber Reck Atwater, Hany Elmaraghy, Luna Sun, Sherry Chen, Chitra Natalie, Stephan Weidinger

Page s147

Poster PDF

Impact Of Day-to-Day Sleep Disruption on The Burden of Disease In Moderate-severe Adult Atopic Dermatitis Patients

Evangeline Pierce, C. Elise Kleyn, Susanne Grond, Jenny Austin, Catherine Reed, Sonja Ständer

Page s148

Poster PDF

Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry

Michael Haft, Keith Knapp, Ami Claxton, Breda Munoz, Sanjeev Balu, Shannon Schnieder, Jonathan Silverberg, Diamant Thaci, Lawrence Eichenfield

Page s149

Poster PDF

Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

Eric L. Simpson, Johnathan Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Haiyun Fan, Saleem A. Farooqui, Gary L. Chan, Justine Alderfer, William Romero, Susan Johnson

Page s150

Poster PDF

Abrocitinib Reduces Skin Pain in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis

Jacob P. Thyssen, Anthony Bewley, Sonja Ständer, Carla Castro, Laurent Misery, Brian S. Kim, Pinaki Biswas, Gary L. Chan, Daniela E. Myers, Melissa Watkins, Justine Alderfer, Erman Güler, Jonathan I. Silverberg

Page s151

Poster PDF

Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN

Jonathan I. Silverberg, Mark Boguniewicz, Kim Papp, Athanasios Tsianakas, Pinaki Biswas, Claire Feeney, Mark Levenberg

Page s152

Poster PDF

Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study

Vivian Shi, Tina Bhutani, Mette Deleuran, Luz Fonacier, Stephen Shumack, Fan Zhang, Michael C. Cameron, Gary L. Chan, Hernan Valdez, Natalie Yin

Page s153

Poster PDF

Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis

Zakiya Rice, Melinda Gooderham, Mark G. Lebwohl, Eric L. Simpson, Mark Boguniewicz, Andreas Wollenberg, Irina Lazariciu, Gary L. Chan, Justine Alderfer, Melissa Watkins

Page s154

Poster PDF